Pathology and Oncology Research (Jun 2022)
Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer
- Zoltán Mátrai,
- Péter Kelemen,
- Csaba Kósa,
- Róbert Maráz,
- Attila Paszt,
- Gábor Pavlovics,
- Ákos Sávolt,
- Zsolt Simonka,
- Dezső Tóth,
- Miklós Kásler,
- Andrey Kaprin,
- Petr Krivorotko,
- Ferenc Vicko,
- Piotr Pluta,
- Agnieszka Kolacinska-Wow,
- Agnieszka Kolacinska-Wow,
- Dawid Murawa,
- Dawid Murawa,
- Jerzy Jankau,
- Slawomir Ciesla,
- Daniel Dyttert,
- Martin Sabol,
- Andrii Zhygulin,
- Artur Avetisyan,
- Alexander Bessonov,
- György Lázár
Affiliations
- Zoltán Mátrai
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
- Péter Kelemen
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
- Csaba Kósa
- Department of Surgery, University of Debrecen, Debrecen, Hungary
- Róbert Maráz
- Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary
- Attila Paszt
- Department of Surgery, Faculty of Medicine, SZTE ÁOK, University of Szeged, Szeged, Hungary
- Gábor Pavlovics
- Department of Surgery, University of Pécs, Pécs, Hungary
- Ákos Sávolt
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
- Zsolt Simonka
- Department of Surgery, Faculty of Medicine, SZTE ÁOK, University of Szeged, Szeged, Hungary
- Dezső Tóth
- Department of Surgery, University of Debrecen, Debrecen, Hungary
- Miklós Kásler
- Minister of Human Capacities, Government of Hungary, Budapest, Hungary
- Andrey Kaprin
- National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Russian Academy of Sciences, Moscow, Russia
- Petr Krivorotko
- N.N.Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
- Ferenc Vicko
- Medical Faculty Novi Sad, Oncology Institute of Vojvodina Sremska Kamenica, University of Novi Sad, Novi Sad, Serbia
- Piotr Pluta
- 0Department of Surgical Oncology and Breast Diseases, Polish Mother’s Memorial Hospital–Research Institute in Lodz, Lodz, Poland
- Agnieszka Kolacinska-Wow
- 1Department of Head and Neck Cancer Surgery, Medical University of Lodz, Lodz, Poland
- Agnieszka Kolacinska-Wow
- 2Department of Surgical Oncology, Cancer Center, Medical University of Lodz, Lodz, Poland
- Dawid Murawa
- 3Clinic of Surgical Oncology, Poznan University of Medical Sciences, Poznan, Poland
- Dawid Murawa
- 4General and Oncological Surgery Clinic, Karol Marcinkowski University Hospital, Zielona Gora, Poland
- Jerzy Jankau
- 5Plastic Surgery Department, Medical University of Gdańsk/University Hospitals, Gdansk, Poland
- Slawomir Ciesla
- 4General and Oncological Surgery Clinic, Karol Marcinkowski University Hospital, Zielona Gora, Poland
- Daniel Dyttert
- 6Department of Surgical Oncology, St. Elisabeth Cancer Institute, Medical Faculty, Comenius University, Bratislava, Slovakia
- Martin Sabol
- 6Department of Surgical Oncology, St. Elisabeth Cancer Institute, Medical Faculty, Comenius University, Bratislava, Slovakia
- Andrii Zhygulin
- 7LISOD Hospital of Israeli Oncology, Kyiv, Ukraine
- Artur Avetisyan
- 8National Center of Oncology, Yerevan, Armenia
- Alexander Bessonov
- 9Breast Cancer Department of the LOKOD, N.N.Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
- György Lázár
- Department of Surgery, Faculty of Medicine, SZTE ÁOK, University of Szeged, Szeged, Hungary
- DOI
- https://doi.org/10.3389/pore.2022.1610377
- Journal volume & issue
-
Vol. 28
Abstract
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Breast Cancer, modified on the basis of the international consultation and conference within the frames of the Central-Eastern European Academy of Oncology. The recommendations cover non-operative, intraoperative and postoperative diagnostics, determination of prognostic and predictive markers and the content of cytology and histology reports. Furthermore, they address some specific issues such as the current status of multigene molecular markers, the role of pathologists in clinical trials and prerequisites for their involvement, and some remarks about the future.
Keywords
